adx-2191
Generic: methotrexate
adx-2191: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Aldeyra Therapeutics, Inc. (ALDX) | Phase 2 |
FDA Decisions
FDA_MeetingFDA granted Fast Track Designation for ADX-2191 for the treatment of retinitis pigmentosa.(ALDX)
Frequently asked questions
Who is developing adx-2191?
adx-2191 is being developed by Aldeyra Therapeutics, Inc..
What is adx-2191's latest FDA decision?
The most recent tracked FDA decision for adx-2191 is FDA_Meeting for FDA granted Fast Track Designation for ADX-2191 for the treatment of retinitis pigmentosa., dated August 19, 2025.
Get deeper analysis on adx-2191
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis